Epirubicin
Epirubicin is an antineoplastic agent in the anthracycline class. It functions as a topoisomerase II inhibitor, intercalating with DNA to inhibit nucleic acid synthesis and induce cell death in rapidly dividing cancer cells.
Dosage by Body Weight
Dosage must be highly individualized and is calculated based on Body Surface Area (BSA) rather than body weight alone. Administered strictly via intravenous infusion by oncology specialists, typically in 21-day cycles.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Not applicable
- Tracking Notes
- Not indicated for self-administration. Pediatric dosing requires strict specialist calculation based on Body Surface Area (BSA).
- Body Weight
- 5-7 kg
- Dose
- BSA-based calculation
- Frequency
- Cyclic therapy (e.g., every 3-4 weeks)
- Tracking Notes
- Requires precise calculation of Body Surface Area (BSA) by a pediatric oncologist.
- Body Weight
- 8-10 kg
- Dose
- BSA-based calculation
- Frequency
- Cyclic therapy (e.g., every 3-4 weeks)
- Tracking Notes
- Requires precise calculation of Body Surface Area (BSA) by a pediatric oncologist.
- Body Weight
- 11-15 kg
- Dose
- BSA-based calculation
- Frequency
- Cyclic therapy (e.g., every 3-4 weeks)
- Tracking Notes
- Requires precise calculation of Body Surface Area (BSA) by an oncologist.
- Body Weight
- 16-20 kg
- Dose
- BSA-based calculation
- Frequency
- Cyclic therapy (e.g., every 3-4 weeks)
- Tracking Notes
- Requires precise calculation of Body Surface Area (BSA) by an oncologist.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Not applicable | Not indicated for self-administration. Pediatric dosing requires strict specialist calculation based on Body Surface Area (BSA). |
| 5-7 kg | BSA-based calculation | Cyclic therapy (e.g., every 3-4 weeks) | Requires precise calculation of Body Surface Area (BSA) by a pediatric oncologist. |
| 8-10 kg | BSA-based calculation | Cyclic therapy (e.g., every 3-4 weeks) | Requires precise calculation of Body Surface Area (BSA) by a pediatric oncologist. |
| 11-15 kg | BSA-based calculation | Cyclic therapy (e.g., every 3-4 weeks) | Requires precise calculation of Body Surface Area (BSA) by an oncologist. |
| 16-20 kg | BSA-based calculation | Cyclic therapy (e.g., every 3-4 weeks) | Requires precise calculation of Body Surface Area (BSA) by an oncologist. |
Formulation
Purpose
Used primarily as an adjuvant therapy in patients with node-positive breast cancer, as well as for treating other malignancies including gastric, ovarian, and lung cancers.
Generic Name
EpirubicinBranded Drug Names
Epirubicin is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.